JP2019515003A - ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 Download PDF

Info

Publication number
JP2019515003A
JP2019515003A JP2018559369A JP2018559369A JP2019515003A JP 2019515003 A JP2019515003 A JP 2019515003A JP 2018559369 A JP2018559369 A JP 2018559369A JP 2018559369 A JP2018559369 A JP 2018559369A JP 2019515003 A JP2019515003 A JP 2019515003A
Authority
JP
Japan
Prior art keywords
mmol
alkyl
tert
butoxy
dimethylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515003A5 (https=
Inventor
エフ． キャドウ，ジョン
エフ． キャドウ，ジョン
ナイドゥ，ビー．ナラシムフル
パテル，マノジュ
エー． ウォーカー，マイケル
エー． ウォーカー，マイケル
ワン，タオ
イン，ジウェイ
ジャン，ジョンシン
バーバラ ジョン，ジジェン
バーバラ ジョン，ジジェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2019515003A publication Critical patent/JP2019515003A/ja
Publication of JP2019515003A5 publication Critical patent/JP2019515003A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018559369A 2016-05-11 2017-05-09 ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 Pending JP2019515003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662334718P 2016-05-11 2016-05-11
US62/334,718 2016-05-11
PCT/IB2017/052701 WO2017195113A1 (en) 2016-05-11 2017-05-09 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2019515003A true JP2019515003A (ja) 2019-06-06
JP2019515003A5 JP2019515003A5 (https=) 2020-04-23

Family

ID=58745295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559369A Pending JP2019515003A (ja) 2016-05-11 2017-05-09 ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Country Status (4)

Country Link
US (1) US10407410B2 (https=)
EP (1) EP3455215A1 (https=)
JP (1) JP2019515003A (https=)
WO (1) WO2017195113A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515000A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565809A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526728A (ja) * 2009-05-15 2012-11-01 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製の阻害剤
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2018523695A (ja) * 2015-08-20 2018-08-23 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515000A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515939A (ja) * 2016-05-11 2019-06-13 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP6782766B2 (ja) * 2015-08-11 2020-11-11 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
AU2008323561B2 (en) 2007-11-15 2013-07-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG10201408512RA (en) 2009-12-23 2015-02-27 Univ Leuven Kath Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014164467A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9527842B2 (en) 2013-03-14 2016-12-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN106170603B (zh) * 2014-02-18 2019-10-01 越洋塞科外汇合营有限公司 用于水下软管替换的方法及设备

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526728A (ja) * 2009-05-15 2012-11-01 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製の阻害剤
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP6782766B2 (ja) * 2015-08-11 2020-11-11 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
JP2018523695A (ja) * 2015-08-20 2018-08-23 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515000A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515939A (ja) * 2016-05-11 2019-06-13 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515000A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Also Published As

Publication number Publication date
EP3455215A1 (en) 2019-03-20
US20190127351A1 (en) 2019-05-02
US10407410B2 (en) 2019-09-10
WO2017195113A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
TWI714590B (zh) 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
JP6782766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
JP2018522909A (ja) ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−縮合三環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
TW201718537A (zh) 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
JP2020503352A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515003A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2023217201A2 (zh) 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN108368093A (zh) 作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物
EP3334723B1 (en) 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2018520162A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515939A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515000A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN107771177A (zh) 作为人类免疫缺陷病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
JP2018519348A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2018522052A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2018522924A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのイミダゾピリジン大環状化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211019